The phase II COAST clinical trial demonstrated improved outcomes using immunotherapy combinations for patients with unresectable stage III non-small cell lung cancer, according to researchers at Yale Cancer Center, Cancer Center of Kansas, University of Colorado, Abramson Cancer Center, Astrazenaca, and collaborating international organizations.
Zachary SteinhartMaxwell FoiseyDebolina GangulySean Yamada-HunterThe Parker Institute for Cancer Immunotherapy, a collaborative consortium of the world’s leading immuno-oncology experts, named its 2024 class of Early Career Researcher awardees.
